Axsome Therapeutics (AXSM) – Analysts’ Recent Ratings Changes

Axsome Therapeutics (NASDAQ: AXSM) has recently received a number of price target changes and ratings updates:

• 1/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 12/31/2024 – Axsome Therapeutics had its price target lowered by analysts at Mizuho from $124.00 to $122.00. They now have an “outperform” rating on the stock.
• 12/31/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/30/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
• 12/12/2024 – Axsome Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $121.00 price target on the stock.
• 11/25/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
• 11/20/2024 – Axsome Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/13/2024 – Axsome Therapeutics had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an “outperform” rating on the stock.
• 11/12/2024 – Axsome Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/12/2024 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.

Axsome Therapeutics Stock Down 1.6 %

NASDAQ AXSM traded down $1.35 on Tuesday, reaching $83.78. The company had a trading volume of 555,429 shares, compared to its average volume of 851,087. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The company’s fifty day moving average is $92.75 and its 200 day moving average is $89.03. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $105.00. The stock has a market capitalization of $4.06 billion, a P/E ratio of -12.83 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the business posted ($1.32) EPS. Sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Axsome Therapeutics

Large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its stake in Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after purchasing an additional 27,534 shares during the period. Franklin Resources Inc. boosted its position in shares of Axsome Therapeutics by 47.5% during the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company’s stock valued at $13,713,000 after purchasing an additional 51,696 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock worth $81,659,000 after buying an additional 23,564 shares during the period. Barclays PLC grew its holdings in Axsome Therapeutics by 279.6% in the third quarter. Barclays PLC now owns 61,785 shares of the company’s stock worth $5,552,000 after purchasing an additional 45,509 shares during the period. Finally, Wellington Management Group LLP increased its position in Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after buying an additional 8,125 shares in the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.